Kyrsten Sinema on Psychedelics, Policy, and Veterans: Inside the New Bipartisan Movement

Divergent States

Divergent States
Kyrsten Sinema on Psychedelics, Policy, and Veterans: Inside the New Bipartisan Movement
Jun 13, 2025 Season 1 Episode 13
Divergent States

In this exclusive interview, former U.S. Senator Kyrsten Sinema joins Divergent States to discuss the future of psychedelic medicine in American healthcare. From Ibogaine and PTSD to policy reform and bipartisan collaboration, Sinema opens up about her firsthand exposure to the healing potential of psychedelics through veterans' experiences - and why the time to act is now.

We explore how veterans are pushing the policy frontier, what FDA and CMS approval would mean, and why even critics of the current political landscape may want to support this shift.

Whether you're skeptical of government or hopeful for reform, this conversation tackles the friction between institutions and innovation—and why psychedelics might be the most disruptive medicine in a generation.

👉 Don’t forget to subscribe, share, and join the conversation

🔑 Key Topics & Takeaways:

  • Sinema’s introduction to psychedelics through Ibogaine and a veteran’s recovery story
  • The bipartisan support behind psychedelic research and its surprising origins
  • Why psychedelic medicine challenges the pharmaceutical business model
  • The risks of corporate monopolization and how small biotech firms can resist buyouts
  • The path to FDA and CMS approval for Ibogaine, MDMA, and psilocybin
  • Why the Trump administration’s staffing of “disruptors” may accelerate reform
  • Access, affordability, and insurance coverage: what’s next
  • Her vision for psychedelic medicine by 2030

⏱️ Chapters:

00:00 – Intro: Politics, Power, and Psychedelics
 01:41 – Why Interview Sinema? Pushback & Intentions
 02:21 – First Sponsor Tease & PS25 Plans
 03:56 – Sinema Joins the Interview
 04:18 – How Ibogaine Changed Her Perspective
 06:49 – Senate Colleagues' Reactions
 07:44 – Policy Progress & Bipartisan Allies
 09:43 – Pharma Capture & Psychedelic Industry Risks
 12:02 – Can Psychedelics Avoid Biotech Monopoly?
 13:40 – Cost, Access, and Equity Concerns
 14:44 – Ensuring Access for the Most Vulnerable
 15:56 – State vs. Federal Models
 17:00 – Federal Role in Decriminalization & Reform
 17:20 – Regrets or Missed Legislative Opportunities?
 18:43 – Sinema’s Continued Involvement
 20:06 – Political Alignment vs. Policy Goals
 20:17 – Restoring Trust in Institutions
 21:55 – Five-Year Outlook for Psychedelic Medicine
 23:10 – Final Reflections & Outro
 23:41 – Bonus: Sinema on Psychedelic Science 2025 Panels
 25:17 – Collaboration with VETS Foundation
 25:53 – Closing Thanks & Conference Plans
 28:49 – Outro Recap & Reflections
 31:19 – Sponsors, Shulgin Legacy, and Fireside Project
 32:10 – Next Episode Tease: Dr. Anne Wagner

Send us a text

Support the show

Special Thanks to our Macrodosers and Heroic Dosers on Patreon, Super D and Lucy!


https://linktr.ee/3L1T3Mod